The latest articles, editorials and news releases from InvestorBrandNetwork (IBN), a growing Investor Brand Platform.
RSS Feed for InvestorBrandNetwork (IBN)May 27, 2026 — Virginia Gov. Abigail Spanberger has vetoed two measures aimed at launching a legal retail cannabis industry, arguing that the proposals arrived too soon and lacked safeguards needed for a responsible rollout.
May 27, 2026 — Disseminated on behalf of Numa Numa Resources Inc. and may include paid advertisements.
May 27, 2026 — Frontieras is advancing its proprietary FASForm(TM) platform, which converts coal into fuels, hydrogen and industrial materials, positioning the resource as a multi-output industrial feedstock capable of supporting modern energy and manufacturing markets. A recent article quotes Matthew McKean, Frontieras cofounder and CEO, discussing the company’s Solid Carbon Fractionation technology.
May 27, 2026 — Amidst increased AI adoption and rising demand, BluSky AI (OTC: BSAI) is advancing a modular, deployment-first approach designed to align infrastructure availability with the growing need for high-performance computing. “The company’s strategy centers on its Distributed Neocloud model, which is being developed to support machine learning workloads and inference computing without the limitations associated with legacy cloud environments,” reads a recent article.
May 27, 2026 — Suntex Enterprises (OTC: SNTX) announced that subsidiary Red Spur Land & Ranch Co. is in advanced negotiations to acquire approximately 100 acres in Texas for a proposed large-scale mixed-use residential and commercial development project.
May 27, 2026 — Earth Science Tech has positioned itself as a diversified healthcare holding company focused on pharmaceutical compounding, telemedicine, healthcare services, and strict capital allocation. The company recently completed a vertically integrated telehealth and pharmacy ecosystem through the launch of MyOnlineConsultation.
May 27, 2026 — Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising.
May 27, 2026 — Astrotech (NASDAQ: ASTC) announced that its board has approved a strategic initiative focused on lunar resource development, autonomous industrial infrastructure and future Moon-based semiconductor and quantum computing manufacturing opportunities tied to NASA’s Artemis and Commercial Lunar Payload Services programs. The initiative will evaluate opportunities involving silicon-28, helium-3, platinum group metals and water ice, alongside technologies supporting lunar silicon purification, semiconductor wafer production, AI and high-performance computing infrastructure, autonomous robotics and quantum cooling systems.
May 27, 2026 — Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.
May 27, 2026 — This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising.
May 27, 2026 — A new doctoral study from Sweden’s Karolinska Institutet has found that sexual difficulties are common among young people who have survived cancer treatment. The nature and severity of those difficulties shift considerably based on cancer type and how intensively the patient was treated.
May 27, 2026 — News has been coming through in recent weeks of different central banks selling off some of their gold reserves in order to have the liquidity they need to shore up their currencies or purchase energy during this time of geopolitical turmoil in the Middle East. While that selloff has taken some steam out of bullion’s bull run, many analysts say this could be setting up the metal for its next climb upwards.
May 27, 2026 — Microsoft and Uber have put a face on a problem spreading through corporate America: AI tools that work but cost much more than anyone planned. The former began phasing out its Claude Code subscriptions in mid-May, with the bulk expiring at the end of June.
May 27, 2026 — The travel industry is changing quickly as more people use artificial intelligence to plan vacations and book hotels. Instead of using short search terms on Google, travelers are now asking AI tools detailed questions in simple language.
May 27, 2026 — This article has been disseminated on behalf of Redwood AI Corp. and may include paid advertising.
May 27, 2026 — GelrinC(R) is positioned as a potential first-in-class, off-the-shelf solution for knee cartilage repair in the U. S.
May 27, 2026 — This article has been disseminated on behalf of Nevada Organic Phosphate Inc. and may include paid advertising.
May 27, 2026 — VolitionRx Limited (NYSE American: VNRX) provided a corporate update highlighting recent clinical and commercial progress, including submission of a feline lymphoma manuscript tied to a potential $5 million milestone payment, alongside continued momentum in licensing discussions with more than a dozen global diagnostic and liquid biopsy companies. The company also highlighted advancements across its diagnostic pipeline, including validation progress for its Capture-Seq cancer detection platform, expansion of its sepsis-focused Nu.
May 27, 2026 — Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD(TM), PrecisionCHD(TM) and the HeartRisk(TM) population insights platform, designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes.
May 27, 2026 — Tonix Pharmaceuticals (NASDAQ: TNXP) announced publication of peer-reviewed Phase 1 data for TNX-1500, its investigational anti-CD40L monoclonal antibody, in the Journal of Clinical Immunology, highlighting favorable safety, tolerability and pharmacodynamic results in healthy volunteers. The study found TNX-1500 was generally well tolerated with no serious adverse events, demonstrated sustained suppression of T cell-dependent antibody responses and showed a half-life supporting monthly intravenous dosing, supporting advancement toward a planned Phase 2 investigator-initiated kidney transplant rejection study in the second half of 2026, pending FDA clearance.